Company:  LIGAND PHARMACEUTICALS IN ... (LGND)
Form Type:  10-Q
Filing Date:  8/8/2019 
CIK:  0000886163 
Address:  3911 SORRENTO VALLEY BLVD
SUITE 110
 
City, State, Zip:  SAN DIEGO, California 92121 
Telephone:  858-550-7500 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$101.57  
Change: 
0.78 (0.77%)  
Trade Time: 
May 29  
Market Cap: 
$1.63B
Trade LGND now with 

© 2020  
Description of Business
We are a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. We employ research technologies such as antibody discovery technologies, structure-based drug design, formulation science and liver targeted pro-drug technologies to assist companies in their work toward securing prescription drug and biologic approvals. We currently have partnerships and license agreements with over 120 pharmaceutical and biotechnology companies. Over 200 different programs are in various stages of commercialization and development and fully funded by our collaboration partners and licensees. We have contributed novel research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and PPD, among others.
Register and access this filing in:     
  FORM 10-Q
    PART I - FINANCIAL INFORMATION
      Item 1. Condensed Consolidated Financial Statements
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        CASH FLOW
        Notes to Condensed Consolidated Financial Statements
          BALANCE SHEET
      Item 2. Management's Discussion and Analysis of Financial ...
      Item 3. Quantitative and Qualitative Disclosures about ...
      Item 4. Controls and Procedures
    PART II. OTHER INFORMATION
      Item 1. Legal Proceedings
      Item 1A. Risk Factors
      Item 2. Unregistered Sales of Equity Securities and Use of ...
      Item 3. Defaults Upon Senior Securities
      Item 4. Mine Safety Disclosures
      Item 5. Other Information
    SIGNATURES
  EXHIBIT 10.1
  EXHIBIT 31.1
    CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
  EXHIBIT 31.2
    CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
  EXHIBIT 32.1
    CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER